Incidence, risk factors and pre-emptive screening for COVID-19 associated pulmonary aspergillosis in an era of immunomodulant therapy

Rebecca van Grootveld*, Martha T. van der Beek, the CAPA2.0 study group, Nico A.F. Janssen, Mehmet Ergün, Karin van Dijk, Carina Bethlehem, Susanne Stads, Judith van Paassen, Leo M.A. Heunks, Catherine S.C. Bouman, Monique H.E. Reijers, Roger J. Brüggeman, Frank L. van de Veerdonk, Sjoerd H.W. van Bree, Charlotte H.S.B. van den Berg, Marnix Kuindersma, Joost Wauters, Albertus Beishuizen, Paul E. VerweijJeroen A. Schouten

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Web of Science)
34 Downloads (Pure)

Abstract

Purpose: COVID-19 associated pulmonary aspergillosis (CAPA) is associated with increased morbidity and mortality in ICU patients. We investigated the incidence of, risk factors for and potential benefit of a pre-emptive screening strategy for CAPA in ICUs in the Netherlands/Belgium during immunosuppressive COVID-19 treatment. Materials and methods: A retrospective, observational, multicentre study was performed from September 2020–April 2021 including patients admitted to the ICU who had undergone diagnostics for CAPA. Patients were classified based on 2020 ECMM/ISHAM consensus criteria. Results: CAPA was diagnosed in 295/1977 (14.9%) patients. Corticosteroids were administered to 97.1% of patients and interleukin-6 inhibitors (anti-IL-6) to 23.5%. EORTC/MSGERC host factors or treatment with anti-IL-6 with or without corticosteroids were not risk factors for CAPA. Ninety-day mortality was 65.3% (145/222) in patients with CAPA compared to 53.7% (176/328) without CAPA (p = 0.008). Median time from ICU admission to CAPA diagnosis was 12 days. Pre-emptive screening for CAPA was not associated with earlier diagnosis or reduced mortality compared to a reactive diagnostic strategy. Conclusions: CAPA is an indicator of a protracted course of a COVID-19 infection. No benefit of pre-emptive screening was observed, but prospective studies comparing pre-defined strategies would be required to confirm this observation.

Original languageEnglish
Article number154272
JournalJournal of Critical Care
Volume76
DOIs
Publication statusPublished - Aug 2023

Bibliographical note

Funding
Funding was provided by the Dutch National Institute for Public Health and the Environment (RIVM) and the ZonMw COVID-19 Programme.

Publisher Copyright: © 2023 The Authors

Fingerprint

Dive into the research topics of 'Incidence, risk factors and pre-emptive screening for COVID-19 associated pulmonary aspergillosis in an era of immunomodulant therapy'. Together they form a unique fingerprint.

Cite this